VBWG
Slides

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial



Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial

Download VBWG06_CHARM.ppt (7 slides - 0.6MB)

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial  CHARM-Added: Study design CHARM-Added: Baseline characteristics by ACEI dose CHARM-Added: Daily ACEI dose CHARM-Added: Primary outcome of CV death or HF hospitalization CHARM-Added: Primary outcome in patients taking a -blocker Summary: CHARM-Added



ACEIcandesartanCHARMRelationship

Related at vwbg.org

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).
More related